These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 28523719

  • 1. Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data.
    Ha KH, Kim B, Choi H, Kim DJ, Kim HC.
    Diabet Med; 2017 Sep; 34(9):1235-1243. PubMed ID: 28523719
    [Abstract] [Full Text] [Related]

  • 2. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
    Wong CKH, Man KKC, Shi M, Chan EW, Ho CW, Tse ETY, Wong ICK, Lam CLK.
    PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
    [Abstract] [Full Text] [Related]

  • 3. Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study.
    Lee SJ, Ha KH, Lee JH, Lee H, Kim DJ, Kim HC.
    PLoS One; 2019 Dec; 14(2):e0211959. PubMed ID: 30742667
    [Abstract] [Full Text] [Related]

  • 4. Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort.
    Cho YY, Cho SI.
    Metabolism; 2018 Aug; 85():14-22. PubMed ID: 29530797
    [Abstract] [Full Text] [Related]

  • 5. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J, Mehta R, Donnelly R, Idris I.
    Ann Med; 2016 Aug; 48(4):224-34. PubMed ID: 26982210
    [Abstract] [Full Text] [Related]

  • 6. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT, Chang KC, Li CY, Wu JS.
    Cardiovasc Diabetol; 2016 Mar 01; 15():41. PubMed ID: 26932742
    [Abstract] [Full Text] [Related]

  • 7. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
    Kim KJ, Choi J, Lee J, Bae JH, An JH, Kim HY, Yoo HJ, Seo JA, Kim NH, Choi KM, Baik SH, Kim SG, Kim NH.
    Cardiovasc Diabetol; 2019 Mar 11; 18(1):28. PubMed ID: 30857540
    [Abstract] [Full Text] [Related]

  • 8. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
    Ekström N, Svensson AM, Miftaraj M, Franzén S, Zethelius B, Eliasson B, Gudbjörnsdottir S.
    Diabetes Obes Metab; 2016 Oct 11; 18(10):990-8. PubMed ID: 27282621
    [Abstract] [Full Text] [Related]

  • 9. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
    Zghebi SS, Steinke DT, Rutter MK, Emsley RA, Ashcroft DM.
    Diabetes Obes Metab; 2016 Sep 11; 18(9):916-24. PubMed ID: 27177784
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Real-world comparison of mono and dual combination therapies of metformin, sulfonylurea, and dipeptidyl peptidase-4 inhibitors using a common data model: A retrospective observational study.
    Lee KA, Jin HY, Kim YJ, Kim SS, Cho EH, Park TS.
    Medicine (Baltimore); 2022 Feb 25; 101(8):e28823. PubMed ID: 35212277
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Progression to insulin for patients with diabetes mellitus using the Texas Medicaid database.
    Rascati KL, Richards KM, Lopez D, Cheng LI, Wilson JP.
    Clin Ther; 2011 Dec 25; 33(12):2016-20. PubMed ID: 22101160
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.